Product Description
Fampridine is a drug that has been shown to improve walking speed for some adults with multiple sclerosis. (Sourced from: https://mstrust.org.uk/a-z/fampridine-fampyra)
Mechanisms of Action: Potassium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Multiple Sclerosis
Known Adverse Events: Back Pain | Dizziness | Headache | Pain Unspecified | Paresthesia | Insomnia | Nasopharyngitis | Pharyngitis | Multiple Sclerosis | Asthenia | Constipation
Company: Acorda
Company Location: ARDSLEY NY 10502
Company CEO: Ron Cohen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2020-002438-34 | P2 |
Active, not recruiting |
Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
2023-11-19 |